Heart failure is an increasing public health issue with substantial morbidity and mortality
rates. This study aimed to evaluate the efficacy, safety, and long-term outcomes of …

Objective: Heart failure (HF) is a growing public health problem with high morbidity and
mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a …

Background: Angiotensin receptor neprilysin inhibitor (ARNI) was recommended by major
guidelines as the frontline therapy for heart failure with reduced ejection fraction (HFrEF) …

Heart failure (HF) is characterized by ventricular remodeling, excessive neurohumoral
stimulation, abnormal myocyte calcium cycling, accelerated apoptosis, and genetic …

Abstract Objectives: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global
Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy …

Background In a large randomized controlled trial (PARADIGM-HF), ARNI has been shown
to significantly reduce cardiovascular mortality and hospitalization for patients with reduced …

Abstract Funding Acknowledgements Type of funding sources: None. Background The goal
of this study is to look at the safety and efficacy of ARNI (valsartan/sacubitril), a combination …

Medicine® Page 1 This Article Has Been Retracted Effect of the angiotensin-receptor-neprilysin
inhibitor in heart failure patients with left ventricular ejection fraction higher than 40 …

Background: The angiotensin receptor-neprilysin inhibitor (ARNI) decreases cardiovascular
mortality in patients with chronic heart failure with a reduced ejection fraction (HFrEF). Data …

Background. We sought to evaluate the long-term effects of angiotensin receptor blocker–
neprilysin inhibitor (ARNI) therapy on reverse remodeling of the failing myocardium in HFrEF …